$2.30 EPS Expected for Jazz Pharmaceuticals plc (JAZZ) as of May, 8

April 16, 2018 - By Benjamin Allen

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Corporate Logo
Big Money Sentiment increased to 1.09 in Q4 2017. It has change of 0.06, from 2017Q3’s 1.03. The ratio improved due to Jazz Pharmaceuticals plc positioning: 30 sold and 89 reduced. 49 funds bought positions and 81 increased positions. Investors holded 53.58 million in 2017Q3 but now own 52.98 million shares or 1.12% less.
Parallax Volatility Advisers L P holds 12,246 shs. Credit Suisse Ag has invested 0.01% of its capital in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Bnp Paribas Arbitrage owns 14,501 shs for 0% of their capital. Brandywine Global Investment Mngmt Limited Company holds 0.17% or 209,076 shs in its capital. Ubs Asset Mgmt Americas invested in 191,773 shs. Mitsubishi Ufj Securities Hldgs Communication Limited stated it has 30 shs or 0.02% of all its holdings. Eaton Vance reported 0.04% stake. Mirae Asset Glob Ltd stated it has 18,845 shs. Moreover, Brave Asset Management has 0.12% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Fjarde Ap holds 20,068 shs or 0.04% of its capital. Moreover, Tekla Capital Ltd Liability Corp has 0.51% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Van Eck Associate Corporation invested in 86,919 shs or 0.06% of the stock. Dimensional Fund Ltd Partnership stated it has 0.01% of its capital in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). 6,567 are held by Hsbc Hldg Public Limited. Ajo L P holds 0.11% or 182,293 shs.

Jazz Pharmaceuticals plc registered $3.80 million net activity with 0 buys and 16 sales since December 11, 2017. 700 shs were sold by Young Matthew P., worth $105,854 on Thursday, March 15. Treacy Paul had sold 877 shs worth $122,446. On Monday, April 2 $150,010 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was sold by COZADD BRUCE C. WILSON KAREN J sold $604,345 worth of stock or 3,899 shs. On Monday, December 11 ENRIGHT PATRICK G sold $1.26M worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ).

On May, 8 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)’s earnings report is anticipated by WallStreet, as reported by RTT. This year’s earnings per share analyst estimate is anticipated to be $2.30. That is 63.12 % up compareed to $1.41 earnings per share for last year. In case of $2.30 earnings per share JAZZ’s profit could be $137.55M. -10.85 % negative EPS growth is what analysts predict. $2.58 earnings per share was published for last [previous quarter]. On during the last trading session the stock decreased $0.11 or 0.07%, reaching $155.96.Currently Jazz Pharmaceuticals plc is downtrending after 0.32% change in last April 17, 2017. JAZZ has also 403,846 shares volume. JAZZ underperformed by 11.87% the S&P 500.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

Total analysts of 17 have positions in Jazz Pharmaceuticals (NASDAQ:JAZZ) as follows: 15 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 88%. Since October 18, 2017 according to StockzIntelligence Inc Jazz Pharmaceuticals has 29 analyst reports. On Wednesday, November 8 the rating was maintained by Wells Fargo with “Buy”. On Friday, October 20 the firm has “Buy” rating given by Piper Jaffray. On Thursday, January 11 BMO Capital Markets maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating. BMO Capital Markets has “Buy” rating and $196.0 target. In Wednesday, November 8 report FBR Capital maintained the stock with “Buy” rating. On Wednesday, November 8 the firm has “Buy” rating given by UBS. In Tuesday, December 5 report Mizuho maintained it with “Hold” rating and $150.0 target. On Sunday, December 3 the firm has “Buy” rating by Cantor Fitzgerald given. On Friday, April 6 the firm has “Buy” rating given by Seaport Global. In Sunday, December 10 report Cantor Fitzgerald maintained it with “Buy” rating and $200.0 target. On Tuesday, January 2 Stifel Nicolaus maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating. Stifel Nicolaus has “Buy” rating and $180.0 target.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally.The company has $9.33 billion market cap. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.The P/E ratio is 19.59. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.